Alector (ALEC) Competitors $1.44 -0.07 (-4.64%) As of 07/7/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALEC vs. EOLS, UPB, XNCR, SAGE, KALV, DNTH, RLAY, IOVA, AMLX, and DNAShould you be buying Alector stock or one of its competitors? The main competitors of Alector include Evolus (EOLS), Upstream Bio (UPB), Xencor (XNCR), Sage Therapeutics (SAGE), KalVista Pharmaceuticals (KALV), Dianthus Therapeutics (DNTH), Relay Therapeutics (RLAY), Iovance Biotherapeutics (IOVA), Amylyx Pharmaceuticals (AMLX), and Ginkgo Bioworks (DNA). These companies are all part of the "pharmaceutical products" industry. Alector vs. Its Competitors Evolus Upstream Bio Xencor Sage Therapeutics KalVista Pharmaceuticals Dianthus Therapeutics Relay Therapeutics Iovance Biotherapeutics Amylyx Pharmaceuticals Ginkgo Bioworks Evolus (NASDAQ:EOLS) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends. Which has more risk & volatility, EOLS or ALEC? Evolus has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, Alector has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Is EOLS or ALEC more profitable? Evolus has a net margin of -20.40% compared to Alector's net margin of -139.74%. Alector's return on equity of -100.58% beat Evolus' return on equity.Company Net Margins Return on Equity Return on Assets Evolus-20.40% -759.04% -20.14% Alector -139.74%-100.58%-25.15% Do institutionals & insiders believe in EOLS or ALEC? 90.7% of Evolus shares are held by institutional investors. Comparatively, 85.8% of Alector shares are held by institutional investors. 6.1% of Evolus shares are held by insiders. Comparatively, 9.1% of Alector shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has stronger valuation & earnings, EOLS or ALEC? Evolus has higher revenue and earnings than Alector. Evolus is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvolus$266.27M2.21-$50.42M-$0.89-10.27Alector$100.56M1.43-$119.05M-$1.26-1.14 Does the media prefer EOLS or ALEC? In the previous week, Alector had 1 more articles in the media than Evolus. MarketBeat recorded 1 mentions for Alector and 0 mentions for Evolus. Evolus' average media sentiment score of 0.00 equaled Alector'saverage media sentiment score. Company Overall Sentiment Evolus Neutral Alector Neutral Do analysts rate EOLS or ALEC? Evolus currently has a consensus price target of $23.75, indicating a potential upside of 159.85%. Alector has a consensus price target of $4.00, indicating a potential upside of 177.78%. Given Alector's higher possible upside, analysts plainly believe Alector is more favorable than Evolus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evolus 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Alector 2 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.14 SummaryEvolus beats Alector on 10 of the 15 factors compared between the two stocks. Get Alector News Delivered to You Automatically Sign up to receive the latest news and ratings for ALEC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALEC vs. The Competition Export to ExcelMetricAlectorMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$150.99M$2.91B$5.52B$9.02BDividend YieldN/A2.44%5.24%4.08%P/E Ratio-1.1420.3027.1920.04Price / Sales1.43250.25413.81108.84Price / CashN/A41.7026.2128.59Price / Book1.127.397.925.55Net Income-$119.05M-$55.04M$3.17B$248.49M7 Day Performance1.41%2.51%1.78%4.87%1 Month Performance-3.36%-0.21%1.26%6.63%1 Year Performance-68.76%3.41%33.30%20.38% Alector Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALECAlector3.8007 of 5 stars$1.44-4.6%$4.00+177.8%-67.2%$150.99M$100.56M-1.14270EOLSEvolus3.6664 of 5 stars$9.14-1.8%$23.75+159.8%-16.4%$589.35M$266.27M-10.27170UPBUpstream BioN/A$10.93-0.1%$56.50+416.9%N/A$587.93M$2.37M0.0038High Trading VolumeXNCRXencor3.9777 of 5 stars$8.14-3.1%$28.00+244.0%-56.4%$579.32M$110.49M-2.66280High Trading VolumeSAGESage Therapeutics3.2033 of 5 stars$9.15-1.4%$8.93-2.4%-14.9%$572.97M$41.24M-1.58690High Trading VolumeKALVKalVista Pharmaceuticals4.2325 of 5 stars$11.41-0.8%$24.83+117.6%+27.7%$567.31MN/A-3.07100News CoverageUpcoming EarningsAnalyst ForecastGap UpHigh Trading VolumeDNTHDianthus Therapeutics1.794 of 5 stars$17.63-2.8%$53.00+200.6%-27.6%$566.98M$6.24M-6.1280High Trading VolumeRLAYRelay Therapeutics2.7797 of 5 stars$3.30-0.6%$17.67+435.4%-44.2%$565.79M$10.01M-1.48330Positive NewsIOVAIovance Biotherapeutics4.6838 of 5 stars$1.69-2.9%$12.22+623.2%-76.6%$564.34M$164.07M-1.36500Trending NewsAMLXAmylyx Pharmaceuticals3.1907 of 5 stars$6.33-2.6%$11.00+73.8%+293.0%$564.26M$87.37M-2.04200High Trading VolumeDNAGinkgo Bioworks1.0925 of 5 stars$9.42-2.0%$5.77-38.8%N/A$551.18M$227.04M-1.03640Gap UpHigh Trading Volume Related Companies and Tools Related Companies Evolus Alternatives Upstream Bio Alternatives Xencor Alternatives Sage Therapeutics Alternatives KalVista Pharmaceuticals Alternatives Dianthus Therapeutics Alternatives Relay Therapeutics Alternatives Iovance Biotherapeutics Alternatives Amylyx Pharmaceuticals Alternatives Ginkgo Bioworks Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALEC) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredInstant Cash (in 4 clicks)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alector, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alector With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
